When Did Ozempic Come Out? Its 2017 FDA Approval and What Followed

Quick answer

Ozempic came out in the United States on December 5, 2017, when the FDA approved Ozempic (semaglutide) injection. The approval covered use with diet and exercise to improve blood sugar control in adults with type 2 diabetes, as the original FDA approval letter states. On the same day, Novo Nordisk said it expected to launch Ozempic in the U.S. in the first quarter of 2018, according to its approval announcement. Approval and pharmacy availability are different milestones.

We wrote this history for women who keep meeting Ozempic in weight-loss headlines and want to know what the dates mean. Every approved use of Ozempic injection is for adults with type 2 diabetes. Weight management was approved for a separate semaglutide product, Wegovy, on June 4, 2021.

The Ozempic timeline at a glance

FDA action dates come from Drugs@FDA and the approval letters cited in this article. The 2018 launch window is Novo Nordisk's expectation as stated in 2017.

What did the 2017 approval cover?

The December 2017 action approved one product, Ozempic injection, under application NDA 209637. The Drugs@FDA record for Ozempic lists that original approval as "Type 1 - New Molecular Entity." The current Ozempic label still carries the header line "Initial U.S. Approval: 2017," a line that federal labeling rules reserve for the year the FDA first approved a new molecular entity. Together, these records show that Ozempic was the first U.S. approval of semaglutide itself.

The approval letter also shows that Novo Nordisk had submitted the application a year earlier, on December 5, 2016. What the FDA approved was a single use: helping adults with type 2 diabetes improve blood sugar control alongside diet and exercise. Weight management was not part of that approval.

Ozempic's label describes it as a glucagon-like peptide-1 (GLP-1) receptor agonist. If that drug class is new to you, our plain explainer on what GLP-1 medication is covers the basics.

When did Ozempic become available?

The FDA approval took effect on the date of the letter. Reaching pharmacies is a separate, commercial step. In its December 5, 2017 announcement, Novo Nordisk said it expected to launch Ozempic in the U.S. in the first quarter of 2018. That was the company's stated plan at the time. The sources we checked do not record the first day a pharmacy dispensed Ozempic, so we do not name one.

So when one source says Ozempic came out in 2017 and another says 2018, both can be right: the first usually means the FDA approval, the second the expected launch.

How did Ozempic's approved uses grow?

The FDA has added two uses to the Ozempic injection label since 2017, each through a supplement to the same application:

• January 16, 2020: to reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal heart attack or non-fatal stroke) in adults with type 2 diabetes and established cardiovascular disease, according to the 2020 supplement approval letter.
• January 28, 2025: to reduce the risk of sustained eGFR decline, end-stage kidney disease and cardiovascular death in adults with type 2 diabetes and chronic kidney disease, according to the 2025 supplement approval letter.

The current Ozempic injection prescribing information, revised May 2026, lists exactly these three uses, and each is for adults with type 2 diabetes. The application history also continues into 2026 with other changes, such as labeling updates. That is one reason a 2017 news story cannot stand in for today's prescribing information.

Ozempic, Rybelsus and Wegovy: one ingredient, separate approvals

Semaglutide is the active ingredient in more than one product, and each product has its own approval record:

• Ozempic injection: first approved December 5, 2017, for adults with type 2 diabetes.
• Rybelsus tablets: first approved September 20, 2019, as a new dosage form for adults with type 2 diabetes, according to the Rybelsus approval record. The current tablet label, revised January 2026, covers both Rybelsus and Ozempic tablets.
• Wegovy injection: first approved June 4, 2021, for chronic weight management in certain adults alongside a reduced-calorie diet and increased physical activity, according to the Wegovy approval letter. In March 2024 the FDA added a Wegovy use to reduce the risk of cardiovascular death, heart attack and stroke in adults with cardiovascular disease and either obesity or overweight, as the FDA news release explains.

A shared ingredient does not make these products interchangeable, and it does not give them the same dates, directions or approved uses. Our side-by-side guide to Wegovy vs. Ozempic compares the products using their current labels. For the tablets, our Ozempic pill guide explains what the current tablet label says, while Rybelsus and weight loss separates the tablet's approved uses from weight research.

Why do websites give different years for Ozempic?

They are usually answering different questions:

• 2016: when Novo Nordisk submitted the application, not when the FDA approved it.
• 2017: the FDA approval of Ozempic injection.
• 2018: the expected U.S. launch.
• 2019, 2021 or later: a different semaglutide product, or a later new use.
• Another country's year: each country's regulator acts on its own timeline.

The labels add one more wrinkle. The current tablet label also prints "Initial U.S. Approval: 2017," even though the tablet application was first approved in 2019. That line follows semaglutide's first U.S. approval, not each product's own date.

Is Ozempic approved for weight loss?

No. Ozempic injection's three approved uses are all for adults with type 2 diabetes, and none of them is weight management. A separate semaglutide product, Wegovy, was approved for chronic weight management in certain adults in June 2021.

If you first heard of Ozempic as a weight-loss medicine, that gap matters: the product named in a headline and the product approved for a purpose are not always the same.

How long has Ozempic been around?

As of November 2026, nearly nine years have passed since the FDA approved Ozempic injection in December 2017. That number describes the age of the approval. It does not describe how long any one person has used the medicine, and later uses and formulations have their own, shorter histories.

What the date does not tell you

A long approval history is easy to read as a personal green light. It is not one. The date tells you when the FDA first acted on one product. It does not answer the questions that shape your own care: whether you are pregnant, planning a pregnancy or breastfeeding, which other medicines you take, your medical history, or exactly which product is being offered. Those answers come from the current label for that exact product and from a clinician who knows your history.

If breastfeeding is part of your decision, our article on Ozempic while breastfeeding explains why the formulation and the evidence matter. Compounded preparations are a separate category: the FDA states that compounded drugs are not FDA-approved, so a compounded preparation does not inherit Ozempic's approval history just because it contains semaglutide. Our explainer on whether compounded semaglutide is FDA-approved covers that question in detail.

How to check an approval date yourself

1. Open the product's page in Drugs@FDA, the FDA's database of approved drugs. Ozempic injection is application NDA 209637.
2. Under "Original Approvals or Tentative Approvals," the action date shows when the product was first approved.
3. Under "Supplements," the category "Efficacy-New Indication" marks a new use. The linked letter says what changed.
4. For current directions and warnings, read the current label on DailyMed rather than an old announcement.

Once you have a prescription, check that the product name on the pharmacy label matches the product whose record you looked up.

This article is for informational purposes only and does not constitute medical advice, diagnosis or treatment. It is a product history, not a recommendation to use any medicine. Medication is prescribed only if a licensed physician determines it is appropriate. Sources checked November 3, 2026.

Telehealth prescribing rules differ by state. Read the state-by-state guide.